Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-001 first-line chemotherapy ± pembrolizumab followed by olaparib or placebo in BRCA non-mutated advanced epithelial ovarian cancer
2022-502124-52-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab and olaparib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (4 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival in PD-L1-positive tumors and Progression-Free Survival in all participants. Started Dec 2018; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2022-502124-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502124-52-00.